Latham & Watkins Advises SQZ Biotechnologies in Public Offering of Common Stock

A capital markets deal team advised the cell therapy company in the offering.

February 16, 2021

SQZ Biotechnologies Company (NYSE: SQZ) (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, has announced the pricing of its underwritten public offering of 3 million shares of common stock at a public offering price of US$20 per share. All of the shares of common stock are being offered by SQZ. In addition, SQZ has granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Latham & Watkins LLP represents SQZ Biotechnologies Company in the transaction with a capital markets deal team led by partners Peter Handrinos and Wesley Holmes, with associates Jennifer Yoon, Danny Shulman and Ashley Petrarca.

The firm also advised SQZ Biotech in its initial public offering.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.